In-Depth Notes on Natriuretic Peptides and Their Therapeutic Potential

Endogenous Stimulation of Guanylate Cyclase

  • Key Stimulators:
    • Nitric oxide (NO) is a primary stimulator.
    • Released by the vascular endothelium, NANC (nitrergic nerves) in various tracts (gastrointestinal, reproductive, respiratory) and some inflammatory cells, including perivascular adipose tissue (PVAT).
    • Neurogenic vasodilator innervation affects cerebral and penile arteries.

Natriuretic Peptide Family

  • Types of Natriuretic Peptides:
    • ANP (Atrial natriuretic peptide): produced in atria.
    • BNP (Brain natriuretic peptide): produced in ventricles.
    • CNP (C-type natriuretic peptide): produced by vascular endothelium.
  • Common Features:
    • All have a 17-peptide ring structure.
    • Identification of natriuretic peptides dates back to 1981.

Natriuretic Peptide Actions

  • Physiological Role:
    • Released in response to increased atrial or ventricular pressure, activating stretch receptors in cardiac myocytes.
    • ANP and BNP released to regulate blood volume.

Mechanism of Action of Natriuretic Peptides

  • Vasodilatory Effects:

    • Primarily leads to arterial dilation, especially in renal arteries, increasing renal blood flow and glomerular filtration.

  • Natriuretic Action:

    • Increases renal excretion of Na+ and H2O through:
    • Enhanced renal blood flow
    • Decreased renin secretion (action on juxtaglomerular cells)
    • Decreased aldosterone secretion (direct action on zona glomerulosa in adrenal cortex)

  • These peptides counteract the Renin-Angiotensin-Aldosterone System (RAAS).

NP Receptors

  • Receptor Types:

    • NPR1 (formerly NPR-A): Potency order ANP = BNP > CNP
    • NPR2 (formerly NPR-B): Potency order CNP > ANP = BNP
    • NPR3 (formerly NPR-C): Binds all three peptides, provides clearance from circulation.

  • Functionality:

    • NPR3 is the most abundant receptor and it mediates the internalization and degradation of natriuretic peptides, limiting their physiological actions.

Therapeutic Applications of Natriuretic Peptides

  • Clinical Relevance:

    • Potential for treating heart failure where RAAS is overactive and hypertension.
    • BNP serves as a biomarker for diagnosing CHF.
    • Investigated for several conditions: myocardial ischemia/infarction, right-sided heart failure, acute pulmonary embolism.

  • Challenges:

    • Short half-life in plasma limits clinical utility.
    • Recombinant human BNP, nesiritide, approved for adjunctive therapy in acute CHF.
    • An synthetic analogue of ANP, anaritide, explored but not marketed.

Novel Therapeutic Targets

  • Enhancing Endogenous Actions:
    • Inhibition of neutral endopeptidases (e.g., candoxatril) shows promising hemodynamic effects, increasing plasma ANP levels and decreasing aldosterone and weight.
    • Sacubitril/Valsartan (Entresto): Combination therapy that blocks angiotensin receptors and inhibits neprilysin, showing improved outcomes in heart failure patients despite higher costs.

Sacubitril/Valsartan Evidence

  • Clinical Trials:
    • The PARADIGM-HF trial demonstrated significant benefits of sacubitril/valsartan over enalapril in reducing cardiovascular death and hospitalizations.
    • Results included 20% relative risk reduction for primary endpoints and favorable side effect profiles compared to traditional ACE inhibitors.

Conclusion and Future Directions

  • Research Implications:
    • Potential roles for NPR3 modulation in pulmonary hypertension and preserving right ventricle function noted.
    • Continued exploration needed on NPR3/C receptor strategies for diastolic dysfunction and neurohumoral modulation.
    • Convergence on NPR-C as a crucial protective receptor warrants further investigation to enhance its therapeutic potential.

Summary

  • Natriuretic peptides play significant roles in cardiovascular regulation and emerging therapeutic avenues focusing on enhancing their effects and receptor modulation.